YTHDF1 Protein Reveals How mTORC1 Drives Different Aspects of Aging
New research identifies YTHDF1 as a key factor that determines how mTORC1 signaling contributes to various aging processes.
42 articles
New research identifies YTHDF1 as a key factor that determines how mTORC1 signaling contributes to various aging processes.
Comprehensive review compares natural compounds, synthetic drugs, and exercise for combating age-related bone loss, muscle weakness, and joint degeneration.
Comprehensive review finds limited human data supporting off-label rapamycin use for healthy aging despite strong animal studies.
Comprehensive review reveals how cellular senescence drives lung aging and disease, highlighting therapeutic potential of senolytics and senomorphics.
Scientists review promising therapies that eliminate or control senescent cells to promote healthier aging and prevent disease.
Groundbreaking multicenter trial will test rapamycin's ability to extend healthy lifespan in companion dogs, offering insights for human aging.
McMaster researcher reveals why current protein recommendations are too low and how resistance training fights aging.
Dr. Fajgenbaum reveals how existing medications can treat diseases they weren't designed for, potentially saving lives.
Scientists discover how cells absorb large therapeutic molecules that shouldn't cross membranes, opening new drug design possibilities.
New research reveals how TSC2 mutations suppress translation of autism and epilepsy genes, offering potential therapeutic targets.
Comprehensive review of TSC reveals mTOR inhibitor successes while identifying critical unmet needs in neuropsychiatric care.
48-week study finds low-dose rapamycin safe with improvements in muscle mass and pain for women, but no major changes in body fat.